Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858446 | 0.85 | CA1 (0.33) | LPLLIPGSNCAALPL | |
| SCHEMBL16428250 | 0.82 | SNCA (0.33) | LPLLIPGEGFRSNCAALPL | |
| SCHEMBL31082970 | 0.81 | GRM4 (0.33) | LPLLIPGEGFRSNCAALPL | |
| SCHEMBL27080065 | 0.77 | SNCA (0.36) | SNCAALPL | |
| SCHEMBL21623497 | 0.77 | LPL (0.33) | LPLLIPGSNCAALPLPDCD1LG2 | |
| SCHEMBL428799 | 0.75 | NNMT (0.40) | ALPLPDCD1LG2CD274 | |
| SCHEMBL423702 | 0.75 | PDCD1 (0.43) | ALPLCD274 | |
| SCHEMBL22160418 | 0.74 | PDE4A (0.32) | — | |
| SCHEMBL24215357 | 0.73 | ALPL (0.37) | SNCAALPL | |
| SCHEMBL19994974 | 0.73 | LPL (0.36) | LPLLIPGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026745-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | MIRUM PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026745-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B13, HSD17B1, HSD17B3 | LPL 373/4885LIPG 572/4885EGFR 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.